Clinical outcomes of emicizumab prophylaxis in hemophilia A with FVIII inhibitors

Abstract

Emicizumab prophylaxis demonstrates substantial efficacy in reducing bleeding episodes in hemophilia A patients with FVIII inhibitors across diverse patient populations. Ten studies encompassing randomized trials, observational cohorts, and registry data show annualized bleeding rates ranging from 0.0 to 4.4 events per year on emicizumab, representing 79-99% reductions compared to previous bypassing agent prophylaxis or episodic treatment. Between 63-88% of patients achieved zero treated bleeding episodes, with particularly marked improvements in joint bleeding. Standard dosing consists of 3 mg/kg weekly for 4 weeks followed by 1.5 mg/kg weekly maintenance, though weekly and every-2-week regimens show comparable efficacy. Safety is favorable, with injection site reactions being most common (3.6-15% incidence) and thrombotic events rare but serious, particularly when combined with high-dose activated prothrombin complex concentrate. Antidrug antibodies developed in 2 of 88 pediatric patients, with one experiencing loss of efficacy. Quality of life improved significantly across multiple domains including physical health, daily functioning, and school attendance. These outcomes appear consistent across age groups from infants to elderly adults and are maintained over follow-up periods extending to 42 months.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Screening

We screened in sources based on their abstracts that met these criteria:

• Population: Does the study include patients diagnosed with hemophilia A with confirmed FVIII inhibitors?
• Intervention: Does the study involve emicizumab administered as prophylactic therapy?
• Clinical Outcomes: Does the study report clinical outcomes related to bleeding, safety, quality of life, or treatment effectiveness?
• Study Design: Is the study design a randomized controlled trial, non-randomized controlled trial, cohort study, case series with ≥5 patients, systematic review, or meta-analysis?
• Data Extractability: Can clinical outcomes be separately identified for hemophilia A patients with inhibitors in this study?
• Study Type: Is this a human clinical study that reports clinical outcomes (not solely in vitro, animal studies, or purely pharmacokinetic/pharmacodynamic studies)?
• Publication Type: Is this a peer-reviewed study with original data (not a conference abstract, editorial, letter, or commentary without original data)?
• Study Duration: For prospective studies, does the follow-up period meet or exceed 12 weeks? (Answer “Yes” if this is a retrospective study or systematic review/meta-analysis)

Data extraction

We asked a large language model to extract each data column below from each paper.

Study Design:

• Study type: Randomized controlled trial (RCT)
• Single center vs multicenter: Multicenter
• Sample size of hemophilia A patients with FVIII inhibitors: 109 male participants
• Study objectives related to emicizumab outcomes: To compare bleeding rates between emicizumab prophylaxis and no prophylaxis in patients with hemophilia A with FVIII inhibitors

Efficacy Outcomes:

• Annualized bleeding rate (ABR) for all bleeds and treated bleeds: 2.9 events (95% CI 1.7-5.0) with emicizumab prophylaxis vs 23.3 events (95% CI 12.3-43.9) with no prophylaxis
• Percentage of patients with zero treated bleeding episodes: 63% in group A
• Breakthrough bleeding episodes: Associated with high cumulative doses of activated prothrombin complex concentrate.
• Reduction in bleeding rate compared to previous treatment: 79% lower than previous bypassing-agent prophylaxis.

Safety Outcomes:

• Most frequent adverse events: Injection-site reactions (15% incidence)
• Serious adverse events: Thrombotic microangiopathy and thrombosis (2 participants each)

Quality of Life:

• Specific quality of life instruments used: Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL), EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-5L)
• Clinically meaningful changes in quality of life: Significant improvements in Haem-A-QoL and EQ-5D-5L scores

Follow-up Duration:

• Median follow-up time on emicizumab: 24.0 weeks overall.

Results

The review included 10 studies evaluating emicizumab prophylaxis in hemophilia A patients with FVIII inhibitors, comprising randomized controlled trials, observational studies, registries, and systematic reviews.

Emicizumab dosing regimens

• Loading Dose: 3.0 mg/kg weekly for 4 weeks
• Maintenance Dose: 1.5 mg/kg weekly
• Frequency: Weekly
• Route: Subcutaneous

Characteristics of included studies

• Sample Size: 10 studies totaling varying patient numbers and median follow-up durations.
• Patient populations spanned all age groups, most studies enrolled severe hemophilia A patients.

Quality of Life Outcomes

• Significant improvements in disease-specific and generic quality of life measures after emicizumab treatment.

Synthesis

Emicizumab’s substantial efficacy in reducing bleeding in hemophilia A patients with FVIII inhibitors has been demonstrated, with various studies showing up to 99% reductions compared to previous treatments. Benefits on quality of life and safety profiles further support its use as an effective prophylactic option{